MRK : Analysis & Opinions

  • Showing 1-100 of 107 items
  • 1
  • 2
  • >>
  1. Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst ...

    December 19, 2014
    Merck (MRK) acquired Swiss biotech privately held company, OncoEthix, and added a promising experimental early-stage candidate, ...
  2. Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst ...

    December 19, 2014
    Tetraphase Pharmaceuticals, Inc. announced positive top-line data from a phase III study evaluating eravacycline for the ...
  3. Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day

    December 18, 2014
    Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day
  4. NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst ...

    December 18, 2014
    A report from Bloomberg indicated that the Shire is considering a potential acquisition of the NPS Pharma.
  5. Roche Submitted NDA for Melanoma Combination Drug - Analyst Blog

    December 16, 2014
    Roche's (RHHBY) subsidiary Genentech and Exelixis announced the submission of NDA for cobimetinib/Zelboraf combination for ...
  6. This ETF Offers Easy Access To Big Pharma

    November 21, 2014
    Pharma investing isn't for everyone, but sector-specific ETFs, such as the iShares Dow Jones U.S. Pharmaceuticals ETF, have ...
  7. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  8. These Companies Could Run Out of Cash Without Tax Reform

    November 12, 2014
    The wave of Republican victories in mid-term elections blew past everyone's expectations and sparked a rally in the markets. ...
  9. Guidance Remains on Weak Side - Ahead of Wall Street

    October 27, 2014
    Stocks aren't expected to do much today, at least not at the open, though this week's busy earnings docket and the Fed meeting ...
  10. Market Watchers Get a Breather - Ahead of Wall Street

    September 22, 2014
    Today's focus seems primarily on China, though next week will bring a host of top-tier Fed-centric data.
  11.  Whether combating river blindness in Zambia or treating arthritis in Canada, Merck continues to prove its worth in the marketplace and among demanding investors.

    How Merck Found Its Way Into Millions Of Medicine Cabinets

    September 15, 2014
    With over $40 billion in revenue from pharmaceutical sales, there's a good chance that you'll be very grateful for one of ...
  12. Q3 Estimates Beginning to Slip - Ahead of Wall Street

    July 29, 2014
    Lower revisions to the magnitude of Q3 estimates will still be a net positive -- we will see how this trend unfolds.
  13. How Can the Market Build from Here? - Ahead of Wall Street

    June 9, 2014
    The broad stock market indexes finished at new all-time highs on Friday after the strong jobs report.
  14. A Cloudy Earnings Picture - Ahead of Wall Street

    April 29, 2014
    Stocks ran up big last year in anticipation of earnings growth resumption down the road and that hope still remains unrealized. ...
  15. Markets Falling? Get Your Defense Ready

    April 14, 2014
    The stock market is getting whacked. The question now for many investors is, what to do about it. The first thing to do ...
  16. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  17. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  18. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  19. AstraZeneca Goes Back To The M&A Well Yet Again

    August 26, 2013
    AstraZeneca's acquisition of Amplimmune could pay big dividends in a decade.
  20. Will Immunotherapy Disrupt The Oncology Market?

    August 20, 2013
    Immunotherapy could radically change the treatment of cancer, and the revenue opportunities for pharmaceutical companies.
  21. Better Margins Can't Hide Merck's Growth Challenges

    July 30, 2013
    Merck's near-term growth is looking weak, but margin improvements and an underestimated pipeline could offer upside.
  22. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  23. Bond Yields Are Rising -- Do Your Stocks Measure Up?

    June 19, 2013
    Long live the bond market bull. It started running in 1980, when a series of interest rate increases by the Federal Reserve ...
  24. After A Good Run, Novartis Looks Fairly Valued

    June 12, 2013
    Novartis is a well-balanced, high-quality pharma with growth credentials, but also a fair valuation today.
  25. Roche, Reloaded

    May 21, 2013
    Roche has one of the best long-term growth profiles in the Big Pharma space
  26. After A Big Rally, Pfizer Might Need Some Rest

    May 21, 2013
    A big rally has brought Pfizer back to fair value.
  27. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  28. The “Healthy” Play In Contract Research Organizations

    April 17, 2013
    The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is mundane ...
  29. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  30. Pfizer Readies Zoetis For Market

    January 23, 2013
    Pfizer filed further details about its tentative spin-off of Zoetis, its animal health business.
  31. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  32. The Market's Next BIG Turnaround Story

    November 1, 2012
    If you've ever wanted to invest in the early stages of a corporate turnaround, read on. Three of the companies below have ...
  33. It's Time to Sell These 4 Surging Stocks

    October 19, 2012
    With the S&P 500 surging roughly 25% in the past 12 months, it's been a great time to have full exposure to the stock ...
  34. Pfizer Looks To Spin Off Animal Health Unit

    August 15, 2012
    Pfizer has filed plans to sell up to 20% of its animal-health unit in the first half of 2013 to focus on human pharmaceuticals. ...
  35. Healthcare Stocks Continuing To Outperform

    July 18, 2012
    These healthcare stocks are still on fire, with potentially more upside left. But is that actually bad for the stock market? ...
  36. Dow 30 Stocks With High Dividends

    June 1, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  37. Eli Lilly Paying Investors To Wait

    May 3, 2012
    The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some time before ...
  38. Exxon Mobil Staying Energetic

    May 2, 2012
    Exxon Mobil doesn't appear to be having any expansion problems whatsoever.
  39. 7 Great Names for Dividend Yield

    March 30, 2012
    Large, dividend-paying equities are good portfolio additions in this low-interest-rate environment, says asset manager Chip ...
  40. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  41. 5 Dow 30 Stocks With Huge Dividends

    February 27, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  42. Pfizer Shrugs Off the Loss Of Lipitor

    February 6, 2012
    Pfizer remains very profitable and has ample cushion to adjust its cost structure to maintain a respectable level of profit ...
  43. 2011 In Review - Pharmaceuticals

    December 29, 2011
    2011 was a surprisingly healthy year for drug stocks.
  44. 4 Long-Term Buy Signs

    December 13, 2011
    Check out four stocks that saw the 50-day cross the 200-day moving average.
  45. 5 Dow 30 Stocks With Huge Dividends

    November 24, 2011
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  46. Is Third Time The Charm For Gilead?

    November 22, 2011
    Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
  47. Dendreon's Chinese Water Torture

    November 3, 2011
    Dendreon's Provenge continues to shape up as a major disappointment.
  48. Protect On The Downside With J&J

    October 21, 2011
    J&J trades at a reasonable forward P/E and offers investors downside protection.
  49. The 3 Highest Yielding Pharma Stocks

    September 30, 2011
    Learn more about three large pharmaceutical companies with the highest current yields.
  50. 2 Oversold High-Yield Stocks

    August 11, 2011
    Two of Big Pharma’s finest are looking quite oversold at current levels, and while risk remains, both pay handsome yields ...
  51. Top Dividend Stocks Owned By The Pros

    August 2, 2011
    Selecting from the top dividend stocks owned by professional investors may give your portfolio a boost.
  52. Three Safe Sectors For The Summer

    July 11, 2011
    With uncertainty beginning to creep back into the markets, investors may want to take a defensive posture.
  53. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  54. Johnson & Johnson Surrenders In Stents

    June 17, 2011
    JNJ makes a tough and surprising, but ultimately wise, decision.
  55. Lipitor: Pfizer's Loss Is Watson's Gain

    June 10, 2011
    With Lipitor coming off its patent soon, there are a couple of drug companies looking to cash in on sales of the generic ...
  56. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  57. Irish Stocks Present Possible Value Play

    March 9, 2011
    Despite its fiscal woes, Ireland' tech story could ultimately become its saving grace.
  58. 5 Oversold Stocks To Watch

    February 23, 2011
    Let's take a look at a few stocks that have recently entered oversold territory because these could be candidates for a short-term ...
  59. Attack Of The Mega-Caps

    February 22, 2011
    These large companies can add protection for investors, in case there are some missteps in the current economic recovery. ...
  60. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  61. A Look At The Drug Makers Of 2010

    December 30, 2010
    Drug makers faced an uphill fight in 2010 and next year is looking to be just as tough.
  62. Large Cap Dividend Stocks For 2011

    December 17, 2010
    Investors interested in yield for the new year might want to consider a package of solid, stable, large cap stocks which ...
  63. Pfizer Ready To Create Value

    December 15, 2010
    Overall, Pfizer is a company with a cheap stock price, earnings power and numerous options to reward shareholders.
  64. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
  65. Expected Increase In Research And Development

    November 8, 2010
    Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact ...
  66. 7 Reasons To Pick ETFs Over Stocks

    November 1, 2010
    As a cost-effective way to achieve a broadly diversified portfolio, including hard-to-own (but worthwhile) assets, ETFs are ...
  67. The Good And Bad Of DuPont's Strength

    October 28, 2010
    DuPont's success confirms an economic recovery, but raises the spectre of inflation.
  68. Should Investors Take A Chance On Savient?

    October 26, 2010
    Savient's inability to sell itself puts almost everything about the company's value in flux.
  69. 5 Dow 30 Stocks With Huge Dividends

    October 1, 2010
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  70. McKesson Valuation Overly Pessimistic

    September 14, 2010
    McKesson's operations continue to grow and health care reform efforts will add millions of new patients into the industry. ...
  71. Bristol-Myers Pays A Premium For Its Partner

    September 10, 2010
    Bristol-Myers is paying a lot, but a successful HCV franchise could be worth much more.
  72. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  73. BP's Management: Will A Change Do The Company Good?

    July 27, 2010
    BP announced that it will replace CEO Tony Haward. How will investors take the news?
  74. Playing Big Pharma With CROs

    July 6, 2010
    Investors looking to play the growth in R&D spending for human drugs should consider CROs.
  75. Stocks To Guard Your Portfolio

    July 1, 2010
    Finding the right stock to reduce volatility is not as exciting, but it is essential to building a lasting portfolio and ...
  76. Pharmaceuticals With Big Returns

    June 22, 2010
    These intriguing Pharmaceuticals currently have big returns.
  77. Stocks That Protect Against Deflation

    June 21, 2010
    Although recent data suggests prices may be falling, inflation may still take over in the long term due to the excess liquidity ...
  78. Invest In The Magazine Portfolio

    May 6, 2010
    Just for fun, I went through advertisers in Canadian House and Home. Despite being a Canadian magazine, well-known names ...
  79. Pfizer Delivers A Healthy Quarter

    May 6, 2010
    Despite forecasting adjusted earnings of over $2 a share for 2010, Pfizer shares remain at $17.
  80. The S&P 500's Cheapest Stocks

    April 27, 2010
    Everybody loves a bargain, but finding a true bargain in the stock market can be a difficult task.
  81. Dividends With Earnings Growth

    April 23, 2010
    These healthcare and pharma companies have a solid dividend and increasing earnings over the last five years.
  82. Lilly's Top-Line Predicament

    April 21, 2010
    Eli Lilly will have more than $5 billion in annual free cash flow over the next few years to try and stem its top-line predicament. ...
  83. Pharmaceutical Profits That Aren't For The Dogs

    March 15, 2010
    Merck and Sanofi-Aventis recently combined their animal health businesses, lending further evidence to the notion that this ...
  84. 5 Stocks With Low P/Es And High Dividends

    June 19, 2009
    Finding undervalued gems can help boost porfolio returns. Check out five potential diamonds in the rough.
  85. Is Pfizer What The Doctor Ordered Or Bad Medicine?

    April 30, 2009
    Explore Pfizer, its earnings and its recent acquisition deal.
  86. Medical Devices: Cure For Ailing Portfolios?

    February 27, 2009
    Find out how these medical device makers may resuscitate your ailing portfolio.
  87. Invest In The Original S&P 500

    February 18, 2009
    An amazing number of the original companies in the S&P 500 index are still trading. I'll pick out some interesting choices ...
  88. Bristol-Myers Pays Healthy Dividends

    February 12, 2009
    Bristol-Myers is among five companies with a great forward annual dividend yield.
  89. Forest Labs Faces Patent Expirations

    January 23, 2009
    This pharma faces patent expirations on its two key drugs, but its valuation reflects these risks and the firm has appealing ...
  90. No More Tears For Johnson & Johnson

    January 23, 2009
    Its wide range of products and international exposure give this stock a positive long-term outlook.
  91. 10 Blue Chips On The Outs

    October 8, 2008
    The market has taken down stocks of all caliber, and these formerly sturdy blue chip stocks are due another look as we wait ...
  92. What Imclone Means To Eli Lilly

    October 7, 2008
    Eli Lilly expands its cancer offering with the acquisition of Imclone. Can the union boost Eli Lilly's floundering stock ...
  93. Merck Needs A New Megaphone

    July 24, 2008
    Learn how Merck's refusal to sell its story to Wall Street is hurting the stock and the few investors who are still hanging ...
  94. Schering-Plough Clears The Way For Growth (SGP)

    February 15, 2008
    The drug maker has a strong product pipeline and timely diversification that should produce big results for long-suffering ...
  95. Schering-Plough's Smoke Screen (SGP)

    January 24, 2008
    CEO Fred Hassan will buy $2 million of company stock after Q4 earnings are released. Should investors follow, or is this ...
  96. Turning The Rumor Mill (DELL, TRMP, NFLX, MRK)

    June 12, 2007
    A roundup of the week's popular news stories and market rumors.
  97. Merck Needs Investor Relations Lesson (MRK)

    May 17, 2007
    A top Merck exec said the company isn't considering any mega mergers. Is this a case of bad IR?
  98. Up on Amgen (AMGN)

    April 30, 2007
    Amgen shares are in a rut, and that could signal opportunity for investors.
  99. Johnson & Johnson Blows Away Q1 (JNJ)

    April 20, 2007
    J&J beat its Q1 consensus number with ease, so where is the stock is headed from here?
  100. Generic Manufacturers Go After Big Pharma

    March 14, 2007
    Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
  • Showing 1-100 of 107 items
  • 1
  • 2
  • >>
Trading Center